FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2623577366> ?p ?o ?g. }

• W2623577366 abstract "PURPOSE: SCCOHT is a rare, poorly differentiated and very deadly ovarian tumor that mainly affects young women with the median age in twenties. Recently, we and others have discovered that the genome of SCCOHT was minimally disturbed compared to common malignancies with the inactivation mutations of SMARCA4 being the only recurrent genetic alternation in SCCOHT genome. SMARCA4 is the ATPase of the SWI/SNF chromatin-remodeling complex, which is the master regulator of gene transcription through controlling the accessibility of chromatin and therefore plays critical roles in many biological processes such as cell cycle control, apoptosis, and differentiation. Recently, a genetic antagonism has been observed between some SWI/SNF complex components and the histone methyltransferase EZH2 of the polycomb repressive complex 2 (PRC2), suggesting that EZH2 may be a vulnerable target in certain SWI/SNF-deficient tumor. Therefore, we aimed to determine the promise of defeating SCCOHT through targeting EZH2 in the present study. METHODS: The EZH2 protein expression was determined by immunohistochemistry on the SCCOHT tissue microarray. Cell viability, cell cycle and apoptosis were measured by crystal violet staining, FACS analysis and live cell imaging with activated caspase-3/7 staining, respectively. The proteomic profiles of SCCOHT cells were determined by Mass Spectrometry using the TMT-labeled peptide fractions. Two SCCOHT xenograft mouse models were established from BIN67 and SCCOHT1 cells, respectively, in immune-deficient mice were used for the evaluation of EPZ-6438 efficacy in vivo. RESULT: All (24/24) SCCOHT expressed abundant EZH2 protein. In comparison to other ovarian cell lines, SCCOHT cells displayed hypersensitivity to two EZH2 inhibitors (GSK126 and EPZ-6438) and EZH2 shRNA. Furthermore, EPZ-6438 induced cell cycle arrest, apoptosis and cell differentiation in SCCOHT cells, accompanying by the induction of genes involved in cell proliferation, apoptosis and differentiation. Treatment of EPZ-6438 in SCCOHT xenograft-bearing mice delayed tumor progression, improved the survival of mice. Further, re-expression of SMARCA4 suppressed the expression of EZH2 and the global level of histone H3K27 trimethylation, induced the expression of PRC2 targets that are induced by EZH2 inhibitors and triggered differentiation of SCCOHT cells. In addition, we also discovered that SCCOHT cells are hypersensitive to multiple inhibitors of histone deacetylase (HDAC), which is known to cooperate with EZH2 to silence certain target genes. Combined treatment of EPZ-6438 and Quisinostat (an HDAC inhibitor) synergistically suppressed the proliferation of SCCOHT cells. CONCLUSION: Our data suggest that EZH2 is a promising therapeutic target for fighting SCCOHT. Combined pharmacological targeting of both EZH2 and HDAC may provide a novel treatment option for SCCOHT patients. Citation Format: Yemin Wang, Shary Chen, Anthony Karnezis, Nancy Dos Santos, Pilar Ramos, Sarah Maines-Bandiera, Christine Chow, Bernard Weissman, Jeffrey Trent, David Huntsman. THE METHYLTRANSFERASE EZH2 IS A VULNERABLE TARGET IN SMALL CELL CARCINOMA OF THE OVARY, HYPERCALCEMIC TYPE (SCCOHT) [abstract]. In: Proceedings of the 11th Biennial Ovarian Cancer Research Symposium; Sep 12-13, 2016; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(11 Suppl):Abstract nr AP32." @default.
• W2623577366 created "2017-06-15" @default.
• W2623577366 creator A5005637278 @default.
• W2623577366 creator A5014964019 @default.
• W2623577366 creator A5032713796 @default.
• W2623577366 creator A5050435091 @default.
• W2623577366 creator A5052006916 @default.
• W2623577366 creator A5071405218 @default.
• W2623577366 creator A5077469476 @default.
• W2623577366 creator A5085086748 @default.
• W2623577366 creator A5087622468 @default.
• W2623577366 creator A5030049018 @default.
• W2623577366 date "2017-05-31" @default.
• W2623577366 modified "2023-09-27" @default.
• W2623577366 title "Abstract AP32: THE METHYLTRANSFERASE EZH2 IS A VULNERABLE TARGET IN SMALL CELL CARCINOMA OF THE OVARY, HYPERCALCEMIC TYPE (SCCOHT)" @default.
• W2623577366 doi "https://doi.org/10.1158/1557-3265.ovcasymp16-ap32" @default.
• W2623577366 hasPublicationYear "2017" @default.
• W2623577366 type Work @default.
• W2623577366 sameAs 2623577366 @default.
• W2623577366 citedByCount "0" @default.
• W2623577366 crossrefType "proceedings-article" @default.
• W2623577366 hasAuthorship W2623577366A5005637278 @default.
• W2623577366 hasAuthorship W2623577366A5014964019 @default.
• W2623577366 hasAuthorship W2623577366A5030049018 @default.
• W2623577366 hasAuthorship W2623577366A5032713796 @default.
• W2623577366 hasAuthorship W2623577366A5050435091 @default.
• W2623577366 hasAuthorship W2623577366A5052006916 @default.
• W2623577366 hasAuthorship W2623577366A5071405218 @default.
• W2623577366 hasAuthorship W2623577366A5077469476 @default.
• W2623577366 hasAuthorship W2623577366A5085086748 @default.
• W2623577366 hasAuthorship W2623577366A5087622468 @default.
• W2623577366 hasConcept C104317684 @default.
• W2623577366 hasConcept C150425827 @default.
• W2623577366 hasConcept C167227067 @default.
• W2623577366 hasConcept C50171091 @default.
• W2623577366 hasConcept C502942594 @default.
• W2623577366 hasConcept C54355233 @default.
• W2623577366 hasConcept C80828422 @default.
• W2623577366 hasConcept C83640560 @default.
• W2623577366 hasConcept C86803240 @default.
• W2623577366 hasConcept C95444343 @default.
• W2623577366 hasConceptScore W2623577366C104317684 @default.
• W2623577366 hasConceptScore W2623577366C150425827 @default.
• W2623577366 hasConceptScore W2623577366C167227067 @default.
• W2623577366 hasConceptScore W2623577366C50171091 @default.
• W2623577366 hasConceptScore W2623577366C502942594 @default.
• W2623577366 hasConceptScore W2623577366C54355233 @default.
• W2623577366 hasConceptScore W2623577366C80828422 @default.
• W2623577366 hasConceptScore W2623577366C83640560 @default.
• W2623577366 hasConceptScore W2623577366C86803240 @default.
• W2623577366 hasConceptScore W2623577366C95444343 @default.
• W2623577366 hasLocation W26235773661 @default.
• W2623577366 hasOpenAccess W2623577366 @default.
• W2623577366 hasPrimaryLocation W26235773661 @default.
• W2623577366 hasRelatedWork W2021051570 @default.
• W2623577366 hasRelatedWork W2067155951 @default.
• W2623577366 hasRelatedWork W2396829420 @default.
• W2623577366 hasRelatedWork W2407836655 @default.
• W2623577366 hasRelatedWork W2427007523 @default.
• W2623577366 hasRelatedWork W2506640762 @default.
• W2623577366 hasRelatedWork W2555859248 @default.
• W2623577366 hasRelatedWork W2562858959 @default.
• W2623577366 hasRelatedWork W2607808741 @default.
• W2623577366 hasRelatedWork W2614032424 @default.
• W2623577366 hasRelatedWork W2741781335 @default.
• W2623577366 hasRelatedWork W2741850853 @default.
• W2623577366 hasRelatedWork W2741971576 @default.
• W2623577366 hasRelatedWork W2770615157 @default.
• W2623577366 hasRelatedWork W2885585336 @default.
• W2623577366 hasRelatedWork W2886522468 @default.
• W2623577366 hasRelatedWork W2915022564 @default.
• W2623577366 hasRelatedWork W3049101641 @default.
• W2623577366 hasRelatedWork W3082141982 @default.
• W2623577366 hasRelatedWork W3088192947 @default.
• W2623577366 isParatext "false" @default.
• W2623577366 isRetracted "false" @default.
• W2623577366 magId "2623577366" @default.
• W2623577366 workType "article" @default.